First Gene Therapy Approved for Pediatric Sanfilippo Syndrome

The US Food and Drug Administration approved Fayuvi (rebisufligene etisparvovec-hopf), establishing the first definitive disease-modifying treatment for mucopolysaccharidosis type IIIA (MPS IIIA). Children born with this rare autosomal recessive disorder lack heparan N-sulfatase, an essential lysosomal enzyme. Without it, cellular glycosaminoglycans accumulate, causing progressive neurocognitive decline, loss of mobility, and premature death typically in adolescence.

Fayuvi utilizes an adeno-associated viral vector (AAV9) engineered to deliver a functional copy of the SGSH gene directly into the central nervous system. In clinical registries evaluating the therapy, treated pediatric patients demonstrated measurable decreases in cerebrospinal fluid heparan sulfate levels alongside preserved developmental milestones compared to natural history controls.

Delivering genetic payloads to human brains requires precise capsid selection to avoid triggering destructive immune responses while securing sufficient neural transduction. Structural prediction models and protein generative networks have focused heavily on AAV capsid design precisely to achieve this degree of central nervous system delivery.

For families navigating rare neurological diagnoses, this decision validates early genomic screening. Confirming a specific enzymatic deficit early provides clear justification to demand genetic testing long before irreversible physical decline begins.